Anupam Rasayan Raises Revenue Growth Forecast To Over 30% From Previous 20-25%

Market snapshot: Anupam Rasayan India has upgraded its revenue growth guidance for FY27 to over 30%, up from the previous baseline of 20–25%. This positive revision is underpinned by solid top-line performance in Q1 FY27 and the integration of J-Hawk's growth. Concurrently, the company is commercializing its novel Ethyl Trifluoroacetate (ETFA) product, targeting a USD 500 million global addressable market, though its revenue contribution will remain minimal in FY27 as scaling begins.

Data Snapshot

• Consolidated total income grew 36% YoY to ₹667.5 cr from ₹490.7 cr in Q1 FY26.
• Consolidated EBITDA increased 35% YoY to ₹174.9 cr from ₹129.2 cr in Q1 FY26, maintaining a stable operating margin of 26.2%.
• Consolidated Profit After Tax rose 5.7% YoY to ₹51.2 cr compared to ₹48.5 cr in Q1 FY26.

What's Changed

• The company raised its projected revenue growth for FY27 to over 30% (comprising 20–25% organic growth and 10–15 percentage points of J-Hawk growth), compared to the previous guidance of 20–25%.
• Transition from traditional batch chemistry to a continuous flow chemistry platform for commercial-scale Ethyl Trifluoroacetate (ETFA) production, establishing a global first-mover advantage.

Key Takeaways

• Q1 FY27 consolidated total income surged 36% YoY to ₹667.5 cr, demonstrating strong underlying business momentum.
• The integration of J-Hawk contributes an incremental 10–15 percentage points to the consolidated growth outlook, pushing total FY27 expectations above 30%.
• ETFA opens an addressable market of USD 500 million to USD 600 million; however, near-term FY27 revenue contribution will be minimal during the commercialization ramp-up.
• A non-binding LOI signed with Basquevolt S.A. represents a potential revenue opportunity of USD 300 million over 10 years, solidifying the long-term order pipeline.

SAHI Perspective

Anupam Rasayan's decision to raise its growth outlook reflects a clear inflection in the specialty chemical cycle. By combining 20-25% organic growth with J-Hawk's integration, the company is targeting over 30% top-line expansion in FY27. Crucially, the move into advanced continuous flow chemistry for ETFA establishes a high-margin technology moat. While ETFA's FY27 contribution is minimal, the pipeline—strengthened by the USD 300 million Basquevolt deal and the Bliss GVS Pharma acquisition—positions the company for structural margin expansion from FY28 onwards.

Market Implications

The upward revision in growth guidance is a highly bullish signal for the broader Indian specialty chemical sector, suggesting that inventory destocking has concluded and demand is returning strongly. Competitors using traditional batch chemistry may face pricing pressure as Anupam Rasayan's flow-chemistry capability reduces costs and enhances throughput.

Trading Signals

Market Bias: Bullish

The upgrade in growth guidance to over 30% and strong Q1 FY27 earnings (36% YoY revenue growth) provide clear near-term triggers. Additionally, high-value tech milestones (ETFA) and the USD 300 million Basquevolt deal establish solid medium-term support.

Overweight: Specialty Chemicals, Contract Development and Manufacturing Organizations (CDMO), Fluorochemicals

Trigger Factors:

• Closing of the Bliss GVS Pharma acquisition expected in the first half of September 2026.
• Sustainability of consolidated EBITDA margin above 26%.
• Commercial offtake and customer validation updates for continuous-flow ETFA production.

Time Horizon: Medium-term (3-12 months)

Industry Context

The specialty chemicals industry is undergoing a shift toward high-value fluorination and advanced flow chemistry. Traditional batch chemistry is highly capital and energy intensive, whereas continuous flow platforms improve asset turnover and ESG metrics, helping Indian manufacturers move up the global pharma and agro value chain.

Key Risks to Watch

• Slower-than-expected customer validation for ETFA could delay revenue contribution beyond FY27.
• Execution and integration risks relating to the pending acquisition of Bliss GVS Pharma.
• Raw material cost volatility, particularly in fluorinating agents, which could impact EBITDA margins.

Recent Developments

In July 2026, Anupam Rasayan signed a Letter of Intent (LoI) with Spain-based Basquevolt S.A. for the supply of specialty battery materials, valued at approximately USD 300 million over 10 years. In May 2026, the company signed a definitive agreement to acquire a 43.3% stake in Bliss GVS Pharma to expand its pharmaceutical CDMO footprint.

Closing Insight

Anupam Rasayan is transitioning from a high-growth volume player into a technology-driven CDMO powerhouse. Raising its guidance to over 30% highlights near-term strength, while the $500 million ETFA market and continuous flow technology solidify its long-term competitive moat.

High Performance Trading with SAHI.